David A Canner, 36Stamford, CT

2020021, Jul 9, 2020

Jan 6, 2020

16/735187

- Cambridge MA, US
Aviv Regev - Cambridge MA, US
Tyler Jacks - Cambridge MA, US
David Canner - Cambridge MA, US

C07K 16/28
C07K 16/24
C07K 16/30
C12N 9/22
A61P 35/00

The present invention discloses novel methods, compositions, and uses thereof for removing or overcoming immunosuppression. More specifically, the methods and compositions disclosed herein target effector Tcells by modulating ST2 and/or IL-33 signaling using pharmaceutical inhibitors and/or genetic ablation, whereby the levels and/or activities of effector Tcells in a tumor microenvironment are inhibited, and the infiltration of effector CD8 cytotoxic T cells into tumor microenvironment increases. As a result, tumor growth is inhibited and tumor volume is reduced. The present invention also provides methods for identifying and isolating effector Tcells in a population of heterogeneous cells.

2020015, May 21, 2020

Nov 22, 2019

16/692624

- Cambridge MA, US
Daniel G. Anderson - Cambridge MA, US
Hidde Ploegh - Brookline MA, US
Robert S. Langer - Cambridge MA, US
Tyler E. Jacks - Cambridge MA, US
David A. Canner - Cambridge MA, US

A61K 39/00
A61K 31/713
A61K 39/12
C12N 15/87
A61K 48/00
A61K 39/002
A61K 9/00
C12N 15/88
A61K 39/145
A61K 9/51

Compositions and methods for modified dendrimer nanoparticle (“MDNP”) delivery of therapeutic, prophylactic and/or diagnostic agent such as large repRNA molecules to the cells of a subject have been developed. MDNPs efficiently drive proliferation of antigen-specific T cells against intracellular antigen, and potentiate antigen-specific antibody responses. MDNPs can be multiplexed to deliver two or more different repRNAs to modify expression kinetics of encoded antigens and to simultaneous deliver repRNAs and mRNAs including the same UTR elements that promote expression of encoded antigens.